These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3097670)

  • 21. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment.
    Fernández-Montolí ME; Díez-Gibert O; Samaniego JM; Balagueró L; Navarro MA
    Fertil Steril; 1995 Mar; 63(3):522-7. PubMed ID: 7851581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gossypol in the treatment of endometriosis and uterine myoma.
    Han ML; Wang YF; Tang MY; Ge QS; Zhou LF; Zhu PD; Sun YT
    Contrib Gynecol Obstet; 1987; 16():268-70. PubMed ID: 3121251
    [No Abstract]   [Full Text] [Related]  

  • 23. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
    McClelland HR; Quinn AJ
    Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of LH-RH agonist therapy in the treatment of endometriosis (German experience).
    Cirkel U; Schweppe KW; Ochs H; Schneider HP
    Prog Clin Biol Res; 1986; 225():189-99. PubMed ID: 3097665
    [No Abstract]   [Full Text] [Related]  

  • 25. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
    Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
    Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex].
    Gesenhues T; Hackenberg R; Diechert U; Duda V; Sturm G; Schulz KD
    Geburtshilfe Frauenheilkd; 1989 Feb; 49 Suppl 1():96-8. PubMed ID: 2522904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of different modalities of LHRH agonist (buserelin) administration on the inhibition of the pituitary-ovarian axis for the treatment of endometriosis.
    Lemay A; Maheux R; Jean C; Faure N
    Prog Clin Biol Res; 1986; 225():157-73. PubMed ID: 3097663
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor.
    Shozu M; Murakami K; Segawa T; Kasai T; Inoue M
    Fertil Steril; 2003 Mar; 79(3):628-31. PubMed ID: 12620453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of uterine fibroma using LH-RH analogs and gestrinone. Limits and indications].
    Erny R; Milliet E
    Rev Fr Gynecol Obstet; 1990 Feb; 85(2):73-7. PubMed ID: 2108483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
    Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
    Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
    Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
    Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of LHRH analogue action in uterine fibroids.
    Shaw RW
    Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of LHRH analogue to obtain reversible castration in a patient with benign metastasizing leiomyoma.
    Hague WM; Abdulwahid NA; Jacobs HS; Craft I
    Br J Obstet Gynaecol; 1986 May; 93(5):455-60. PubMed ID: 3085706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical application of a gonadotropin releasing hormone analog (buserelin) in the treatment of uterine leiomyomas.
    Acar B; Posaci C
    Int J Gynaecol Obstet; 1992 May; 38(1):52-3. PubMed ID: 1348994
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin.
    Biberoglu K; Gursoy R; Yildiz A
    Gynecol Endocrinol; 1991 Jun; 5(2):109-22. PubMed ID: 1833953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone.
    Perl V; Marquez J; Schally AV; Comaru-Schally AM; Leal G; Zacharias S; Gomez-Lira C
    Fertil Steril; 1987 Sep; 48(3):383-9. PubMed ID: 2957235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
    Hilário SG; Bozzini N; Borsari R; Baracat EC
    Fertil Steril; 2009 Jan; 91(1):240-3. PubMed ID: 18249392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical study on effect of Tripterygium wilfordii Hook. f. on uterin leiomyoma].
    Gao Y; Chen D
    Zhonghua Fu Chan Ke Za Zhi; 2000 Jul; 35(7):430-2. PubMed ID: 11776193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of gonadotropin-releasing hormone agonists before myomectomy.
    Friedman AJ
    Clin Obstet Gynecol; 1993 Sep; 36(3):650-9. PubMed ID: 8403611
    [No Abstract]   [Full Text] [Related]  

  • 40. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist.
    Healy DL; Fraser HM; Lawson SL
    Br Med J (Clin Res Ed); 1984 Nov; 289(6454):1267-8. PubMed ID: 6437510
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.